1,295 DEAD in UK Following COVID Bioweapon Shots – Italy Halts AstraZeneca Shots After Teen Dies
By Brian Shilhavy | Health Impact News | June 11, 2021
The UK Government’s reporting system for COVID vaccine adverse reactions from the Medicines and Healthcare products Regulatory Agency released their latest report yesterday, June 10, 2021.
The report covers data collected from December 9, 2020, through June 2, 2021, for the three experimental COVID “vaccines” currently in use in the U.K. from Pfizer, AstraZeneca, and Moderna.
They report a total of 1,295 deaths and 922,596 injuries recorded following the experimental COVID injections.
Here are the breakdowns from the three shots:
- AstraZeneca: 863 deaths and 717,250 injuries. (Source.)
- Pfizer- BioNTech: 406 deaths and 193,768 injuries. (Source.)
- Moderna: 3 deaths and 9243 injuries. (Source.)
- Unspecified COVID-19 injections: 22 deaths and 2335 injuries. (Source.)
Meanwhile, Italy announced today that it was halting use of the AstraZeneca injections for people under the age of 60, following the death of a teenager who died from blood clots.
Danish drug regulator FAINTS at press conference announcing AstraZeneca vaccine halt
RT | April 14, 2021
Denmark will completely abandon the rollout of AstraZeneca’s Covid-19 vaccine due to a risk of rare blood clots. One of the country’s top drug officials passed out at a press conference delivering the news.
As National Health Board Director Soeren Brostroem announced the decision, the Danish Medicines Agency’s acting director of pharmacovigilance, Tanja Erichsen, fainted and collapsed to the ground.
Erichsen’s fall sparked panic, as Brostroem and other officials rushed over to check on her. The medicines agency later announced that she had regained consciousness, but was taken to hospital for a checkup. No explanation was given for her fainting.
Denmark was the first country in the world to suspend the rollout of AstraZeneca’s Vaxzevria shot in March, though a number of other countries followed suit, among them France, Germany, Italy and Spain. Denmark, however, is the first country in the world to permanently ditch the British-Swedish developed jab.
“In the midst of an epidemic, it has been a difficult decision to continue our vaccination program without an effective and readily available vaccine against Covid-19,” Brostroem said at the press conference. “However, we have other vaccines at our disposal, and the epidemic is currently under control.”
The suspension is expected to push the country’s vaccination timeline back by “some weeks,” according to a report from Danish broadcaster TV2.
Denmark began vaccinations in December, and has to date approved four vaccines – from AstraZeneca, Johnson & Johnson, Moderna and Pfizer/BioNTech. Only two shots, from Moderna and Pfizer, are currently available to Danes, after Johnson & Johnson delayed its own European rollout on Tuesday, due to several cases of blood clots being reported in the US.
AstraZeneca Recruiting 5 Year-Old Kids For Covid Vaccine Trial
By Richie Allen | February 14, 2021
AstraZeneca is planning a childhood immunisation programme that it says, could protect people from Covid-19 for most of their lives. Yesterday the company announced it was recruiting kids as young as five for the trials. Children participating in the trial will get their first jab by the end of this month. Pfizer is planning a similar trial on a global scale.
AstraZeneca believes that by giving children a “series of jabs” in early life, they’d be giving them a lifetime of immunity from Covid. Professor Sarah Gilbert, an Oxford scientist who worked on the AstraZeneca vaccine said:
“If they get infected it will just be a mild disease, it won’t be very serious, it will just be a sniffle. We’re all really waiting to see how things play out. We could be looking at giving young children immunity, and then boosting it towards the end of life.”
Children are basically immune from coronavirus. Most of them will never get it and those who do will have mild symptoms only. Kids DO NOT need a coronavirus vaccine. What’s going on? A Five-year old should not be compelled to participate in a vaccine trial. The child cannot give informed consent. Any parent who puts their child forward for the trial is guilty of neglect and I’d go further than that. It’s child abuse.
They’re already giving as many as 16 vaccines to children in this country, most of them totally unnecessary. Now they want to vaccinate them just in case they get Covid as an adult? It’s insane. Is there any opposition to this anywhere? The answer is no. The papers and the broadcasters just repeat this crap. None of them has the balls to challenge it. I despair.
Richie Allen is the host of The Richie Allen Radio show, Europe’s most listened to independent radio show and is a passionate supporter of free speech. He lives in Salford with the future Mrs Allen and their two dogs.
UK Intelligence to Fight Anti-Vaccine Propaganda Spread by State Actors, British Media Reports
Anti-vaccine demonstrators in Edinburgh © Sputnik / Jason Dunn
By Tim Korso – Sputnik – 09.11.2020
A UK intelligence unit, known as the Government Communications Headquarters (GCHQ), has been authorised to conduct cyber operations to tackle the spread of anti-vaccine propaganda online, The Times reported citing an anonymous government source. According to the newspaper, the government increasingly views anti-vaxxers as a new priority because of the upcoming registration of domestically-developed vaccines against the coronavirus.
Apart from GCHQ, a secretive UK Army unit within the 77th Brigade specialising in information warfare will be taking part in the efforts “to quash rumours about misinformation” related to the COVID-19 vaccines, General Sir Nick Carter confirmed to The Times.
The newspaper’s source claims that GCHQ will be using the same toolkit it utilised to combat Daesh and its propaganda and recruitment efforts. The toolkit includes ways of taking down undesired content and conducting cyber attacks against the cyberactors behind it, for example by encrypting the perpetrators’ computer data, The Times added.
“GCHQ has been told to take out anti-vaxxers online and on social media. There are ways they have used to monitor and disrupt terrorist propaganda”, the anonymous source claimed.
However, GCHQ will not be able to use its tools against everyone online because its authority only extends to dealing with [alleged] state cyber actors and the content created by them, the newspaper reported citing another anonymous government source.
Russia as Main target for UK Intelligence Cyber Operations?
The British newspaper claims Russia will be the GCHQ’s prime target, citing its own investigation into the country’s alleged ties to the surge of internet memes questioning the safety of the vaccine developed by Oxford University in concert with AstraZeneca. The said investigation was based on a trove of documents and images provided by an anonymous source, who claimed to be part of an alleged propaganda effort purportedly seeking to hurt the image of the British vaccine. The Times, however, admitted in its article that it could not directly link the alleged social media campaign, targeting only the UK vaccine, with the Kremlin.
According to the newspaper, the alleged campaign against the AstraZeneca/Oxford vaccine started after the head of the Russian Direct Investment Fund (RDIF) that developed Sputnik V, Kirill Dmitriev, called the UK-developed medicine a “monkey vaccine” on several occasions. Dmitriev referred to the vaccine’s usage of a monkey virus as a vector to deliver the COVID-19 material needed to form immunity. He did not directly call the drug dangerous or ineffective, but noted that the use of human adenoviruses was more reliable, as their influence on the human body is better understood.
Dmitriev’s use of the term “monkey vaccine” prompted the emergence of numerous internet memes, baselessly alleging that the British drug would be turning recipients into monkey-like creatures or otherwise negatively affecting patients’ health. The head of RDIF later denounced the use of his words to besmirch the UK-developed vaccine, but defended his concerns over the possibility of its long-term side effects.
COVID-19: RDIF Points to Absence of Long-Term Studies on Vaccines Based on Monkey Adenoviral Vectors
By Aleksandra Serebriakova – Sputnik – 09.09.2020
The third round of trials for the AstraZeneca anti-COVID-19 drug is now on pause over “potentially unexplained illness” in a participant in the UK. On 11 August, Russia registered its own Sputnik V anti-coronavirus vaccine, which is said to have been developed in a different way.
The Russian Direct Investment Fund (RDIF) the investor which has funded the development of Russia’s Sputnik V anti-coronavirus vaccine, could not comment on the halt of AstraZeneca trials, it said in a statement.
However, RDIF pointed out that the fund’s CEO Kirill Dmitriev had previously discussed the differences between the human adenoviral vector-based platform used in Russia’s Sputnik V vaccine and those used by some of their international colleagues, that rely on “novel unproven technologies such as monkey adenoviral vectors or mRNA”.
“The safety of the human adenoviral vector used in Sputnik V has been proven over decades in over 250 clinical studies, as human adenovirus has been shown to be the safest vaccine delivery mechanism and the most ‘organic for humans’, as human adenovirus has coexisted with humans for over 100,000 years,” RFID said.
Meanwhile, “mRNA and monkey adenoviral vector-based platforms have not been studied over a long period of time,” RDIF CEO Dmitriev pointed out this Tuesday.
Commenting on the so-called “pledge of safety” earlier voiced by the CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer and Sanofi in relation to the development of the first COVID-19 vaccines, Dmitriev stressed that this plea was “insufficient” as it did not “discuss the lack of long-term studies on the carcinogenic effects and impact on fertility of newly-developed vaccine technologies”.
“Since some of the companies developing these vaccines have taken the ‘pledge of safety’, we would like to stress that public health and safety requires not only short-term evidence of a lack of serious adverse effects, but also the safety and efficacy proved by the results of long-term studies,” Dmitriev added.
AstraZeneca COVID-19 Vaccine Trials on Pause
It was revealed this week that the third round of trials for the AstraZeneca anti-COVID-19 vaccine has been halted due to a “potentially unexplained illness” which had developed in a participant in the United Kingdom, without further specifications about the nature of possible side effects. The vaccine in question was developed in partnership with Oxford University and has reportedly involved around 30,000 participants in the UK, US, Brazil and South Africa. AstraZeneca described the pause as “routine” so as to allow for a “standard review process” of “safety data”.
Russia’s First Anti-Coronavirus Vaccine
On 11 August, Russia registered the world’s first vaccine against COVID-19, called Sputnik V, which was developed by the Gamaleya National Research Centre of Epidemiology and Microbiology and the RDIF after several rounds of clinical trials. On Monday, the vaccine was made available to the public.
According to RDIF, Russia has now received requests for 1 billion doses of the vaccine; at least 20 countries, including the UAE, Saudi Arabia, Indonesia, Philippines, Mexico, Brazil and India, have expressed an interest in obtaining Sputnik V.
The Withering of Big Pharma?
By Martha Rosenberg | Dissident Voice | November 7, 2013
It used to be when a drug company settled illegal marketing charges that millions took its drugs under false pretenses, the news would be released on a Friday afternoon when no one would notice. That was then. Now almost all the drug companies have joined the Off label/Kickback club and the public doesn’t seem to notice or care.
On the surface, Johnson & Johnson’s $2.2 billion settlement this week for illegally marketing drugs to the elderly, children and the mentally disabled looks like a victory. J&J’s subsidiary, Janssen Pharmaceuticals, will plead guilty to illegally promoting the antipsychotic Risperdal for “controlling aggression and anxiety in elderly dementia patients and treating behavioral disturbances in children and in individuals with disabilities,” reports Reuters. The promotions included a brazen kickback scheme to Omnicare Inc, a pharmacy supplying nursing homes, exposed by a whistleblower.
At least 15,000 elderly people in nursing homes die a year from drugs like Risperdal said FDA drug reviewer David Graham in Congressional testimony a few years ago. Eli Lilly who makes the similar drug Zyprexa and AstraZeneca who makes Seroquel have also settled charges that they churned the elderly drug market at the price of Grandma and Grandpa’s lives.
But it is not a victory. J&J made $24.2 billion off Risperdal from 2003 to 2010 and shareholders won’t even notice this week’s nano loss. J&J milked Risperdal for all it was worth and the patent had already run out by the time it was charged with illegal schemes. Other drug giants charged with illegal marketing schemes–Abbott for Depakote, Pfizer for Bextra, Eli Lilly for Zyprexa, AstraZeneca for Seroquel, GlaxoSmithKline for Paxil and Merck for Vioxx–also got their money’s worth before the trivial nuisance of suit. Many, like Pfizer who illegally marketed its seizure drug Neurontin while under probation for illegal Lipitor activities–are brazen and shameless repeat offenders.
Many say the only justice that will get Big Pharma’s attention is frog marching the CEOs off to prison and/or cutting them off from their lucrative public trough of Medicare, Medicaid and military health programs.
Still, Big Pharma’s audacious business plan of asking forgiveness not permission is winding down. Not because Pharma, prescribers, consumers, regulators and health officials have seen the light but because there are no more big drugs to pimp. An estimated 100,000 workers will be losing their jobs at Pfizer, Sanofi, Roche, GlaxoSmithKline, AstraZeneca and Merck reported Yahoo finance last month.
Only two new drug campaigns seem to be brewing and they require a major suspension of reality on the part of doctors and patients. One tries to convince people with low back pain they actually suffer from ankylosing spondylitis an arthritis-like condition that causes chronic inflammation of the spine. If your spine is stiff when you wake up in the morning you can take an immune suppressor like Humira which puts you at risk of tuberculosis and lethal viral, fungal and bacterial infections while costing you $12,000 to $17,000 a year. Line forms to the left.
The other, even more brazen campaign, tries to convince people with insomnia, tiredness during the day, moodiness and relationship problems that they actually suffer from Non-24-Hour Sleep–Wake Disorder, a disorder that affects mostly blind people. You don’t have to be blind to have the disorder, says the new Pharma message even though there have been fewer than 100 cases of sighted people with non-24 reported in the scientific literature. It sounds like a stretch but so did convincing people with job, money and marriage problems they really had depression or bipolar disorder.
Still it is obvious the bloom has fallen off the Big Pharma rose and it is now paying the piper for the high-flying party with drug settlements like Johnson & Johnson’s this week. But that doesn’t mean shady marketing, hidden risks, kickbacks and outrageous prices are gone from the medical field. They have just moved to the Medical Device industry.
~
Martha Rosenberg is a columnist/cartoonist who writes about public health. Her first book, titled Born with a Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp the Public Health, has just been released by Prometheus Books. She can be reached at: martharosenberg@sbcglobal.net.
Related article
As “Blockbuster Drug” Bubble Bursts, Big Pharma Takes Jobs Overseas
By Martha Rosenberg | Dissident Voice | March 12th, 2012
It is no consolation to the roughly one out of 600 families who lost their homes in the U.S. but Wall Street made a lot of money slicing and dicing mortgages it knew would implode, while hiding risks. Financial giants, like AIG, are still buzzing along and neither penalties or new laws will prevent a future crash, say financial analysts, because the risky business models have not really changed.
A similar Big Pharma bubble, leavened with risky blockbuster drugs that also blew up, is now bursting. Like Wall Street’s bundled high risk loans, the “tide” created by Big Pharma’s high risk drugs raised many ships during the 2000s from advertising, public relations and medical communication agencies to TV and radio stations, medical journals and doctor/pitchmen who shoveled in its marketing budgets. But now the joy ride is over and Pharma is shedding jobs and settling billions in claims without changing its risky business model, like Wall Street.
In Europe, governments are no longer willing to pay the high prices for drugs that they once did say published reports and some countries are drafting laws making drug makers “prove their drugs are effective or risk having them dropped from the coverage list, or covered at a lower rate.” Imagine!
Germany has already saved 1.9 billion euros in 2011 by refusing to pay higher prices for drugs unless they are clearly superior to existing medicines, and Pharma worries that other countries will also get tough and want scientific proof for drug effectiveness instead of marketing and spin. In the U.S. and elsewhere, a drug only needs to be superior to no drug (placebo) to be approved by regulators — yet “new” is conveyed as “better than any drug to date” in advertising. Some clinicians say Haldol, an inexpensive antipsychotic, and lithium, a similar affordable bipolar drug are better than blockbuster antipyschotics and bipolar drugs that created Pharma’s 2000 bubble.
Before the Vioxx scandal and major settlements over blockbuster drugs like Zyprexa, Bextra, Celebrex, Geodon and Seroquel, being a Pharma rep was probably the next best thing to working on Wall Street. Direct-to-consumer advertising did your pre-sell for you, and all you had to do was show up with your snappy Vytorin tote bag and samples case. Some Pharma reps had their own reception room with ice water, swivel chairs, and laptop ports at medical offices, and most waltzed in to see the doctor right in front of waiting and sick patients. (It didn’t hurt that reps were usually “hotties,” both men or women).
But, by 2011, the bloom had fallen off Pharma reps’ roses. The number of prescribers willing to see most reps fell almost 20 percent, the number refusing to see all reps increased by half, and eight million sales calls were “nearly impossible to complete,” reported ZS Associates. Blockbuster drugs that were found to be unsafe after their big sales push or even withdrawn altogether, did not help the reps’ credibility with doctors. After the aggressively marketed hormone therapy was linked to high incidences of cancer, stroke and heart attack, Wyeth (now Pfizer) announced it was eliminating 1,200 jobs and closing its Rouses Point, New York plant where Prempro products were manufactured.
As government and private insurers increasingly say, “You want us to cover what?” about expensive, dangerous drugs that are not even proven effective, Pharma bubble jobs are evaporating. Almost 20,000 jobs have vanished at AstraZeneca, Novartis and Pfizer in the last 12 months alone. (AstraZeneca scrapped 21,600 more since 2007). Meanwhile, Pharma is outsourcing more of its operations to poor countries.
Workers and people willing to be trial subjects are both a bargain in poor countries where many can’t understand drug risks or refuse them if they did (and most can’t afford the very drugs they help sell). In January the Argentinian Federation of Health Professionals accused drug maker GlaxoSmithKline of misleading participants and pressuring poor families into joining a trial for the Synflorix vaccine, which the company says protects against bacterial pneumonia and meningitis, reported CNN. In 2010, 10 deaths occurred during Pfizer and AstraZeneca drug trials at the Bhopal Memorial Hospital and Research Centre which was ironically built for survivors of the 1984 Bhopal gas disaster, reports MSNBC. 3,878 workers perished in Bhopal when chemicals leaked at a Union Carbide pesticide plant.
Outsourcing drug manufacturing to cheap venues also contributes to Pharma’s cascade of “quality control” problems in which drugs are mislabeled, contaminated or otherwise made dangerous. It is speculated that Johnson & Johnson’s CEO William Weldon “was pushed to retire because of all of the quality issues at McNeil as well as with the company’s hip implant products, which have resulted in a raft of litigation,” reports FiercePharma.
Like the Wall Street bubble, the Pharma bubble was built on products that industry, but not the public, knew were risky, sold for quick profits. Now regulators are examining some of these “assets” more closely and with disturbing findings. The FDA now warns that bestselling statin drugs like Lipitor and Crestor, even approved for children, are linked to memory loss and diabetes associated with. The equally well selling proton pump inhibitors like Nexium and Prilosec for acid reflux disease (GERD) are now believed to increase the risk of bone fractures by 30 percent.
In March, the FDA even rejected a Merck drug that combines the active drug in Lipitor with the active drug in Zetia and Vytorin, a drug that Forbes calls Son of Vytorin. Vytorin (the father) was advertised to treat both food and family “sources of cholesterol” until results from a study that Merck and Schering-Plough appeared to withhold from regulators showed the drug had no effect on the buildup of plaque in the arteries (believed to correlate with heart attack and stroke). There was such a gap between marketing and science, Sen. Chuck Grassley (R-Iowa) asked the General Accounting Office to investigate why the FDA was approving “drugs that appear to have little to no effect in protecting lives and increasing health.”
Yet even as clouds develop over Pharma’s top-selling drugs, some say the FDA is too hard on new drugs, not too easy. “The FDA is impeding useful innovations in the U.S.,” says former FDA deputy commissioner Scott Gottlieb in the a Wall Street Journal oped and lagging behind other countries. Former FDA commissioner Andrew Von Eschenbach, also writing in the WSJ, agrees. The FDA should improve U.S. drug competitiveness by allowing drugs “to be approved based on safety, with efficacy to be proven in later trials,” while the public is already taking the drugs. Isn’t that what’s happening now?
~
Martha Rosenberg is a columnist/cartoonist who writes about public health. Her first book, titled Born with a Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp the Public Health, will be published in April 2012 by Amherst, New York-based Prometheus Books. She can be reached at: martharosenberg@sbcglobal.net.
Related articles
- The drugs don’t work for AstraZeneca (independent.co.uk)
- AstraZeneca to axe 7,000 jobs as revenues slump (independent.co.uk)
- AstraZeneca appoints new chairman for troubled times (independent.co.uk)
- Shorting Candidate AstraZeneca – Seekingalpha.com (seekingalpha.com)